Author

Keisuke Shigeta

Harvard UniversityORCID 0000-0002-9405-9446Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaron N. HataiD· 1 shared Atrayee BhattacharyaiD· 1 shared Chendi LiiD· 1 shared Donald W. KufeiD· 1 shared Hiroki KomatsudaiD· 1 shared Hiroki OzawaiD· 1 shared Jiehui DengiD· 1 shared Kentaro NonakaiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron N. HataORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, Hiroki Ozawa, Keisuke Shigeta, Mai Onishi, Kentaro Nonaka, Takefumi Komiya, Hiroki Komatsuda, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Chendi Li, Jiehui Deng, Aaron N. Hata, Kwok‐Kin Wong, , Donald W. Kufe

This study identifies M1C as a driver of sotorasib resistance in NSCLC KRAS G12C mutant tumors and shows that targeting M1C improves treatment outcomes.

Oncogene · Aug 5, 2026Peer-reviewedCancer Biology